Free EMR Newsletter Want to receive the latest news on EMR, Meaningful Use, ARRA and Healthcare IT sent straight to your email? Join thousands of healthcare pros who subscribe to EMR and HIPAA for FREE!!

$10 Finger Stick Blood Tests Illustrate New Quantified Future

Posted on July 3, 2015 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

I’ve often talked about the variety of health sensors that are quantifying everything about us and how that’s going to change healthcare as we know it. As we have more information about ourselves, it’s impossible for us to keep doing the same things we’ve been doing. One of the challenges we’ve faced with this change is that we need access to the blood to really do quality testing. No one wants to do a venous blood draw to regularly monitor their health data.

This is why I’m so interested in what the quite secretive Theranos is doing with their finger stick blood tests. Yesterday, the big news hit that Theranos got their first FDA clearance for their herpes simplex 1 virus IgG test. Although, as MedCityNews notes, this is the first of 100 pre-submissions they have underway with the FDA.

This is exciting news, but this part of the MedCityNews article is even more exciting for me:

Its HSV-1 test costs $9.07 – one of 153 tests the company says it makes that cost less than $10.

This is a great price point for a lab test and we’d all benefit from this massive decrease in price. I’m still not sure Theranos should have a $9 billion valuation. They still have a long way to go with the FDA, but if they’re able to execute then maybe that valuation isn’t that crazy after all.

Regardless of how Theranos does as a business, I think we’re going to see hundreds of companies like Theranos that continue to make testing more affordable. That’s going to change how we approach healthcare.

Mark Cuban’s Suggestion to Do Regular Blood Tests

Posted on April 24, 2015 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

I’ve been really intrigued by the tweets from Mark Cuban and the response from many to his tweets from those in the healthcare IT community. Here’s a summary of the 3 tweets which ignited the discussion:

  1. If you can afford to have your blood tested for everything available, do it quarterly so you have a baseline of your own personal health
  2. create your own personal health profile and history. It will help you and create a base of knowledge for your children, their children, etc
  3. a big failing of medicine = we wait till we are sick to have our blood tested and compare the results to “comparable demographics”

My friends Dan Munro and Gregg Masters have both been writing a lot about the subject, but there are many others as well. They’ve been hammering Mark Cuban for “giving medical advice” to people when he’s not a doctor. I find these responses really ironic since many of the people who are railing against Mark Cuban are the same people who are calling for us to take part in the quantified self movement.

What I think these people who rail against Mark Cuban want to say is: Don’t misunderstand what Mark’s saying. More testing doesn’t always improve healthcare. In fact, more testing can often lead to a lot of unneeded healthcare.

This is a noble message that’s worthy of sharing. However, I think Mark Cuban understands this. That’s why one of his next tweets told people to get the tests, but don’t show the results to their doctors until they’re sick. In fact, Mark even suggests in his tweets that the history of all these tests could be beneficial to his children and their children. He also calls it a baseline. Mark’s not suggesting that people get these blood tests as a screening for something, but as a data store of health data that could be beneficial sometime in the future.

How is Mark Cuban storing the results of a bunch of blood tests any different than him storing the results from his fitbit or other health sensor?

One problem some people have pointed out is that if you’re doing these blood tests as a baseline, then what if the blood tests weren’t accurate? Then, you’d be making future medical decisions based on a bunch of incorrect data. This is an important point worth considering, but it’s true of any health history. Plus, how are we suppose to make these blood tests more accurate? If the Mark Cuban’s of the world want to be our guinea pigs and do all these blood tests, that’s fine with me. Having them interested in the data could lead to some breakthroughs in blood testing that we wouldn’t have discovered otherwise.

Along with improving the quality of the data the tests produce, it’s possible that having all of this data could help people discover something they wouldn’t have otherwise seen. Certainly any of these possible discoveries should go through the standard clinical trial process before being applied to patients broadly. However, researchers only have so much time and so many resources to commit to clinical trials. Could all the data from a wide swatch of blood tests better help a research identify which research or clinical trials are worth pursuing first? I think so.

For me it all goes back to the wide variety of health sensors that are hitting the market. A blood test is just a much more powerful test than many of the health sensors we see on the market today. So, the warning to be careful about what you read into all these blood tests is an incredibly important message. However, with that fair warning, I don’t see any problem with Mark’s suggestion. In fact, I think all of the extra data could lead to important discoveries that improve the quality of the tests and what measurements really matter.